<http://webisa.webdatacommons.org/prov/184164285>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/75943328> .
<http://webisa.webdatacommons.org/75943328>	<http://www.w3.org/ns/prov#wasQuotedFrom>	<faqs.org> .
<http://webisa.webdatacommons.org/prov/346201256>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/75943328> .
<http://webisa.webdatacommons.org/75943328>	<http://www.w3.org/ns/prov#value>	"The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.2012-01-05" .
<http://webisa.webdatacommons.org/prov/341410079>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/75943328> .
<http://webisa.webdatacommons.org/prov/182831063>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/75943328> .
<http://webisa.webdatacommons.org/75943328>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/prov#Entity> .